Researchers projected CT use in 2023 would lead to more than 100,000 future cancer diagnoses, and if trends continued, may ...

As recently as March, the FDA approved the IL-23 inhibitor guselkumab (Tremfya, Johnson & Johnson/Janssen) for patients with Crohn’s disease, offering both IV and subcutaneous induction options.

Careful examination of clinical trial data and a better understanding of risk factors can help rheumatologists determine if a ...

Using an ophthalmic exoscope with an augmented reality headset instead of a standard operating microscope may yield ergonomic ...

In this video, Ursula A. Matulonis, MD, shares that although data from the REFRaME-O1 trial of luveltamab tazevibulin were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer ...

In this video, Ursula A. Matulonis, MD, discusses preliminary efficacy and safety results for puxitatug samrotecan in patients with recurrent endometrial cancer.Findings from a phase 1/2a study of ...

In this video, Ursula A. Matulonis, MD, discusses new data on rinatabart sesutecan, or Rina-S, for patients with advanced ovarian cancer, which were presented at Society of Gynecologic Oncology Annual ...

In this video, Ursula A. Matulonis, MD, discusses results from the phase 3 MIRASOL trial of mirvetuximab soravtansine-gynx for patients with folate receptor alpha-positive, platinum-resistant ovarian ...

The U.S. and China reached an agreement that will temporarily lower the recent high tariffs on Chinese goods, including Chinese-origin eye wear products, according to a Vision Council press release.

Immunoengineering, which has been beneficial to other medical specialties, could be used in the infectious diseases field to ...

Treatment with lecanemab infusion was safe and generally well-tolerated within an outpatient memory clinic setting, with few infusion-related reactions and a low number of withdrawals due to adverse ...

When we are looking at the role of a mental health professional, we are bridging this gap between physical healing and ...